Get the Stockscreener App
4.09
8.69%
0.35
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $4.09, with a volume of 1.82M.
It is up +8.69% in the last 24 hours and up +92.65% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$3.74
Open:
$3.86
24h Volume:
1.82M
Relative Volume:
0.84
Market Cap:
$197.34M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-2.9638
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
+13.87%
1M Performance:
+92.65%
6M Performance:
+220.08%
1Y Performance:
-84.24%
1-Day Range:
$3.82
$4.0877
1-Week Range:
$3.39
$4.28
52-Week Range:
$1.15
$33.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
4.085 | 180.67M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.56 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.80 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.13 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Sentiment analysis tools applied to Cassava Sciences Inc. Equity WarrantDip Buying & Smart Allocation Stock Reports - newser.com
Published on: 2025-10-13 08:27:20 - newser.com
Exit strategy if you’re trapped in Cassava Sciences Inc.Index Update & Community Shared Stock Ideas - newser.com
Is Cassava Sciences Inc. Equity Warrant a candidate for recovery play2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Published on: 2025-10-13 08:03:22 - newser.com
What the charts say about Cassava Sciences Inc. todayPortfolio Value Report & Expert Verified Stock Movement Alerts - newser.com
How risky is Cassava Sciences Inc. stock nowAnalyst Upgrade & Capital Efficient Trading Techniques - newser.com
Will Cassava Sciences Inc. stock outperform Dow Jones indexGDP Growth & Weekly High Conviction Trade Ideas - newser.com
Why Cassava Sciences Inc. stock is favored by pension fundsJuly 2025 Analyst Calls & Free Long-Term Investment Growth Plans - newser.com
Can Cassava Sciences Inc. Equity Warrant stock maintain operating marginsQuarterly Profit Review & Safe Investment Capital Preservation Plans - newser.com
Visual trend scoring systems applied to Cassava Sciences Inc.2025 Technical Patterns & Risk Managed Investment Signals - newser.com
Chart overlay techniques for tracking Cassava Sciences Inc. Equity WarrantWeekly Gains Summary & Verified Technical Signals - newser.com
What analysts say about Cassava Sciences Inc Equity Warrant stockLow Risk Investment Ideas & Free Daily Stock Hotspot Analysis - earlytimes.in
Cassava Sciences Inc. stock outlook for YEARJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Risk vs reward if holding onto Cassava Sciences Inc. Equity WarrantShare Buyback & Verified Entry Point Detection - newser.com
What data driven models say about Cassava Sciences Inc.’s futureQuarterly Earnings Summary & Real-Time Volume Surge Alerts - newser.com
What indicators show strength in Cassava Sciences Inc.Market Performance Summary & Verified Momentum Stock Alerts - newser.com
Understanding Cassava Sciences Inc. Equity Warrant’s price movementJuly 2025 Rallies & Target Return Focused Stock Picks - newser.com
Pattern recognition hints at Cassava Sciences Inc. upsideWeekly Gains Summary & Weekly Watchlist for Consistent Profits - newser.com
Will Cassava Sciences Inc. (PX91) stock beat growth indexes2025 EndofYear Setup & Safe Swing Trade Setups - newser.com
Can Cassava Sciences Inc. Equity Warrant hit a new high this monthQuarterly Portfolio Report & Weekly Chart Analysis and Guides - newser.com
Should you hold or exit Cassava Sciences Inc. Equity Warrant nowJuly 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
Is Cassava Sciences Inc. (PX91) stock a buy during volatile marketsJuly 2025 Trends & Weekly Return Optimization Alerts - newser.com
How hedge fund analytics apply to Cassava Sciences Inc. Equity Warrant stock2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Chart based exit strategy for Cassava Sciences Inc.Earnings Miss & Real-Time Volume Analysis Alerts - newser.com
Can Cassava Sciences Inc. Equity Warrant recover in the next quarterWeekly Trend Report & Smart Swing Trading Alerts - newser.com
Using RSI to spot recovery in Cassava Sciences Inc. Equity Warrant2025 Price Momentum & Community Verified Trade Alerts - newser.com
Can Cassava Sciences Inc. Equity Warrant stock attract ESG capital inflowsJuly 2025 Short Interest & Weekly Chart Analysis and Guides - newser.com
Cassava Sciences Inc. Equity Warrant stock trend outlook and recovery pathInsider Selling & Weekly Top Gainers Trade List - newser.com
LUCID CAPITAL MARKETS Initiates Coverage of Cassava Sciences (SAVA) with Buy Recommendation - Nasdaq
Cassava Sciences (SAVA): Lucid Capital Markets Initiates Coverage with Buy Rating | SAVA Stock News - GuruFocus
Lucid Capital Upgrades Cassava Sciences(SAVA.US) to Buy Rating, Raises Target Price to $8 - 富途牛牛
How to build a dashboard for Cassava Sciences Inc. Equity Warrant stockTrade Performance Summary & Growth Focused Stock Pick Reports - newser.com
Will Cassava Sciences Inc. (PX91) stock benefit from mergers2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
Will Cassava Sciences Inc. stock gain from lower inflationGap Up & Weekly Chart Analysis and Trade Guides - newser.com
Is Cassava Sciences Inc. (PX91) stock a safe buy pre earningsMarket Movement Recap & Smart Investment Allocation Tips - newser.com
Can Cassava Sciences Inc. Equity Warrant stock continue upward trendTrade Risk Report & Weekly Sector Rotation Insights - newser.com
Cassava Sciences Inc. Equity Warrant stock daily chart insightsRecession Risk & Real-Time Market Trend Scan - newser.com
Is Cassava Sciences Inc. Equity Warrant meeting your algorithmic filter criteria2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Cassava Sciences Inc. Equity Warrant stock retracement – recovery analysisExit Point & Low Drawdown Trading Strategies - newser.com
FRST Stock Analysis and ForecastFederal Reserve Announcements & Free Long-Term Investment Planning - earlytimes.in
Is Cassava Sciences Inc a good long term investmentMACD Trading Signals & Investment Timing Techniques - earlytimes.in
Best data tools to analyze Cassava Sciences Inc. Equity Warrant stock2025 Trading Recap & Growth Oriented Trade Recommendations - newser.com
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
| Kupiec James William | Chief Medical Officer |
Nov 29 '24 |
Sale |
3.87 |
4,000 |
15,480 |
0 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):